 PALO ALTO, Calif., Nov. 25, 2020 PRNewswire -- Eiger BioPharmaceuticals, Inc. Nasdaq:EIGR, focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration FDA has approved... 